Krystal Biotech, Inc.
KRYS· Nasdaq· Biological Products, (No Diagnostic Substances)
- Market cap
- –
- P/FCF
- –
- EV/Sales
- –
- FCF margin
- 48.5%
- ROIC, 5 yr avg
- –
- Revenue, 5 yr CAGR
- –
We record prices for the companies we cover; KRYS is not one of them yet.
Company statistics
Profile · FY2025
- Market cap
- –
- Enterprise value
- –
- Diluted shares
- 30.0M
- Revenue
- $389.1M
- Free cash flow
- $188.9M
- Owner earnings
- $134.4M
Valuation · FY2025
- P/E
- –
- P/FCF
- –
- P/Owner earnings
- –
- EV/Sales
- –
- EV/FCF
- –
- P/B
- –
Margins · FY2025
- Gross
- –
- Operating
- 41.5%
- Net
- 52.6%
- Free cash flow
- 48.5%
- Owner earnings
- 34.5%
- Stock pay
- 14.0%
Returns
- ROIC, FY2025
- –
- ROIC, 5 yr avg
- –
- ROE, FY2025
- 16.8%
- ROE, 5 yr avg
- -2.2%
Growth (CAGR)
- Revenue, 3 yr
- –
- Revenue, 5 yr
- –
- Revenue, 9 yr
- –
- Diluted EPS, 3 yr
- –
- Diluted EPS, 5 yr
- –
- Diluted EPS, 9 yr
- –
- Free cash flow, 3 yr
- –
- Free cash flow, 5 yr
- –
- Free cash flow, 9 yr
- –
Financial health · FY2025
- Cash and investments
- $827.8M
- Total debt
- –
- Net cash
- –
- Debt/Equity
- –
- Debt/FCF
- –
Shareholder returns · FY2025
- Dividend yield
- –
- Payout ratio
- –
- Buyback yield
- –
- Shareholder yield
- –
- Share count, 5 yr
- 9.8%
Financials: ten years from the 10-Ks
Revenue
$389.1M
FY2025
FY2016FY2025
Margins
Operating41.5%Net52.6%
FY2025
FY2016FY2025
Free cash flow and owner earnings
Free cash flow$188.9MOwner earnings$134.4M
FY2025
FY2016FY2025
Diluted shares
30.0M
+59.4% over 9 years, net dilution
FY2016FY2025
Net cash
–
$49.6M more cash than debt
FY2016FY2025
Every figure, year by year
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| The business | ||||||||||
| Revenue | – | – | – | – | – | $0 | $0 | $50.7M | $290.5M | $389.1M |
| Revenue growth | – | – | – | – | – | – | – | – | 473.0% | 33.9% |
| Gross margin | – | – | – | – | – | – | – | – | – | – |
| Operating margin | – | – | – | – | – | – | – | -216.2% | 22.6% | 41.5% |
| Net income | -$1.1M | -$7.9M | -$10.9M | -$19.1M | -$32.2M | -$69.6M | -$140.0M | $10.9M | $89.2M | $204.8M |
| Net margin | – | – | – | – | – | – | – | 21.6% | 30.7% | 52.6% |
| Diluted EPS | – | – | – | – | $-1.71 | $-3.13 | $-5.49 | $0.39 | $3.00 | $6.84 |
| Return on invested capital? | – | – | – | – | – | – | – | – | – | – |
| Cash | ||||||||||
| Operating cash flow | -$1.3M | -$3.9M | -$9.4M | -$18.7M | -$26.1M | -$47.9M | -$100.6M | -$88.8M | $123.4M | $200.9M |
| Capital expenditure | $15.0K | $210.0K | $2.2M | $6.4M | $14.8M | $68.3M | $53.0M | $11.8M | $4.2M | $12.0M |
| Free cash flow | -$1.3M | -$4.1M | -$11.7M | -$25.1M | -$40.9M | -$116.3M | -$153.5M | -$100.6M | $119.2M | $188.9M |
| Stock-based compensation | $33.0K | $246.0K | $792.0K | $1.2M | $3.3M | $15.3M | $33.2M | $39.9M | $49.1M | $54.5M |
| Owner earnings? | -$1.4M | -$4.3M | -$12.5M | -$26.3M | -$44.2M | -$131.6M | -$186.8M | -$140.5M | $70.1M | $134.4M |
| Free cash flow per share | – | – | – | – | $-2.18 | $-5.24 | $-6.02 | $-3.63 | $4.01 | $6.31 |
| Capital allocation | ||||||||||
| Dividends paid | – | – | – | – | – | – | – | – | – | – |
| Share repurchases | – | – | – | – | – | – | – | – | – | – |
| Diluted shares | – | – | – | – | 18.8M | 22.2M | 25.5M | 27.8M | 29.7M | 30.0M |
| Share count change? | – | – | – | – | – | 18.1% | 14.8% | 8.9% | 7.2% | 0.7% |
| Balance sheet | ||||||||||
| Cash and equivalents | $1.9M | $49.6M | $103.7M | $187.5M | $268.3M | $341.2M | $161.9M | $358.3M | $344.9M | $496.3M |
| Short-term investments | – | – | $8.1M | $6.2M | $3.0M | $96.8M | $217.3M | $173.8M | $252.7M | $331.5M |
| Total debt | $1.1M | $0 | – | – | – | – | – | – | – | – |
| Net debt | -$778.0K | -$49.6M | – | – | – | – | – | – | – | – |
| Shareholders' equity | $289.0K | $49.5M | $113.2M | $202.9M | $292.1M | $593.6M | $522.2M | $778.6M | $946.4M | $1.2B |
Latest filings
| 2026-08-03 | 8-K | Earnings release |
| 2026-08-03 | 10-Q | Quarterly report |
| 2026-05-04 | 10-Q | Quarterly report |
| 2026-04-03 | DEF 14A | Proxy statement |
| 2026-02-17 | 8-K | Earnings release |
| 2026-02-17 | 10-K | Annual report |
| 2026-01-12 | 8-K | Earnings release |
| 2025-11-03 | 8-K | Earnings release |
| 2025-11-03 | 10-Q | Quarterly report |
| 2025-08-04 | 8-K | Earnings release |
More from our coverage
- MSFTPlatforms8.4MicrosoftThe most entrenched software franchise in the enterprise, now spending its cash flow on AI capacity; a great business we would own with a margin of safety, not at any price.Base value $410.29
- NVDAAI infrastructure8.4NVIDIAThe best business in technology at the top of its cycle: the moat is CUDA as much as silicon, but today's margins are a peak, not a floor.Base value $104.32
- AAPLHardware7.6AppleOne of the highest-quality businesses in the world growing in the low single digits; the price usually assumes more growth than the numbers show.Base value $134.27
- GOOGLPlatforms7.4AlphabetSearch pays for everything, and AI is both its biggest threat and its biggest opportunity; the price has to allow for search being worth less than it was.Base value $209.60
- NOWSoftware7.4ServiceNowA rare enterprise platform still growing above 20% with high retention; the free cash flow is real but stock pay takes a large share of it.Base value $189.13
- ADBESoftware7.4AdobeSuperb margins and a shrinking share count, priced for decline; the question is whether AI makes Adobe's tools more valuable or makes them unnecessary.Base value $449.35
